- Zulresso is the first FDA approved medication to treat postpartum depression.
- This 60 hour IV infusion is delivered at Barnes Jewish Hospital.
- Zulresso may be the right choice for you if you are experiencing moderate to severe depression and had a baby within the past year.
Update: At this time, the WUSM PBHS Zulresso (Brexanolone) study has been discontinued. In August 2023, the FDA approved the first oral medication specifically indicated for treating postpartum depression. Zurzuvae (zuranolone) is now available by prescription. Read more about it here.
What can I expect from Zulresso (Brexanolone)?
Zulresso is given to you in the hospital through a continuous intravenous (IV) infusion over 3 days At Barnes-Jewish Hospital. This takes place in the antepartum unit (an OB floor) in comfortable rooms with space for your family to visit. If you have another adult with you, your baby can also stay in this room during the day.
What is Zulresso (Brexanolone)?
Zulresso is the first FDA-approved drug to treat postpartum depression (PPD).
In clinical studies, new parents treated with Zulresso experienced a greater reduction in symptoms of PPD vs placebo in 2.5 days. Symptoms were measured at the beginning of treatment using a standard depression scale and again at the end of treatment. In these studies, new parents who took Zulresso generally still felt better 30 days after treatment began.
Next Steps:
At this time, the WUSM PBHS Zulresso (Brexanolone) study has been discontinued. In August 2023, the FDA approved the first oral medication specifically indicated for treating postpartum depression. Read more about it here.
